Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.
暂无分享,去创建一个
A. Zanetti | G. Marano | S. Pupella | S. Vaglio | G. Liumbruno | G. Grazzini | L. Romanò | M. Tosti | L. Catalano | C. Velati | V. Piccinini | Ilaria Pati | G. Facco | Liviana Catalano
[1] S. Sauleda,et al. Epidemiological trends of HIV‐1 infection in blood donors from Catalonia, Spain (2005‐2014) , 2017, Transfusion.
[2] R. Burbano,et al. Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil , 2017, Transfusion.
[3] S. Glynn,et al. A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors , 2017, Transfusion.
[4] S. O’Brien,et al. Donor deferral policies for men who have sex with men: where are we today? , 2016, Current opinion in hematology.
[5] H. Kamel,et al. Risk factors for retrovirus and hepatitis virus infections in accepted blood donors , 2015, Transfusion.
[6] S. Pupella,et al. Changing blood donor screening criteria from permanent deferral for men who have sex with men to individual sexual risk assessment: no evidence of a significant impact on the human immunodeficiency virus epidemic in Italy. , 2013, Blood transfusion = Trasfusione del sangue.
[7] J. Allain,et al. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services , 2012, Vox sanguinis.
[8] S. Stramer,et al. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. , 2012, Transfusion medicine reviews.
[9] P. Cochat,et al. Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[10] J. Lefrère,et al. Estimate of the residual risk of transfusion‐transmitted human immunodeficiency virus infection in sub‐Saharan Africa: a multinational collaborative study , 2011, Transfusion.
[11] M. Vermeulen,et al. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms , 2011, Transfusion.
[12] A. Zanetti,et al. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey , 2008, Transfusion.
[13] R. Dodd,et al. A method for estimating incidence rate of infectious diseases among first‐time blood donors , 2008, Transfusion.
[14] A. Giampaolo,et al. Residual risk of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy , 2005, Transfusion.
[15] K. Soldan,et al. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[16] S. Glynn,et al. A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.
[17] S. Laperche,et al. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[18] K. Soldan,et al. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[19] A. Hall,et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993–2001 , 2003, Vox sanguinis.
[20] A. Keller,et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT , 2002, Transfusion.
[21] S. Glynn,et al. International application of the Incidence Rate/Window Period model , 2002, Transfusion.
[22] S. Stramer,et al. Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population , 2002, Transfusion.
[23] R. S. Ross,et al. Transmission of hepatitis C virus. , 2001, The New England journal of medicine.
[24] J. Barbara,et al. Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood , 2000, BMJ : British Medical Journal.
[25] S. Kleinman,et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study , 1997, Transfusion.
[26] K. Calman,et al. Cancer: science and society and the communication of risk , 1996, BMJ.
[27] S. Kleinman,et al. The Risk of Transfusion-Transmitted Viral Infections , 1996 .
[28] G. Satten,et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. , 1995, The New England journal of medicine.